Screener
Vir Biotechnology, Inc. VIR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Change in fair value of equity investments | 1,893 | (3,000) |
| Change in estimated fair value of contingent consideration | 240 | 11,010 |
| Payment of contingent consideration in excess of acquisition date fair value | — | (17,140) |
| Stock-based compensation | 24,478 | 26,510 |
| Non-cash restructuring, long-lived assets impairment and related charges | — | 399 |
| Other non-cash items, net | 123 | 59 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 6,059 | 5,937 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s stock-based comp?
- Vir Biotechnology, Inc. (VIR) reported stock-based comp of $12.39M in Q2 2026.
- How has Vir Biotechnology, Inc.'s stock-based comp changed year-over-year?
- Vir Biotechnology, Inc.'s stock-based comp decreased by 0.5% year-over-year, from $12.45M to $12.39M.
- What is the long-term trend for Vir Biotechnology, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s stock-based comp has grown at a -12.5% compound annual growth rate (CAGR), from $83.78M to $49.07M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Vir Biotechnology, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude